Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indoximod with Chemotherapy in Newly Diagnosed AML
NCT02835729Phase 1Completed
- Sponsor
- Lumos Pharma, Inc.
- Start
- Jul 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of indoximod in acute myeloid leukemia (AML) (2 arms), sponsored by Lumos Pharma, Inc. Primary endpoints: Safety assessed by development of RLT, AEs and laboratory parameters at 6 months and Serum concentrations (Cmax/Steady State) at 6 months. Started Jul 2016; status: completed.
02
Drugs
indoximod
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02835729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02835729.